4D Molecular Therapeutics Stock
4D Molecular Therapeutics’ mission is to design and develop transformative gene therapy products using our proprietary.
Sign up today and learn more about 4D Molecular Therapeutics Stock
Invest in or value your shares in one or many pre-IPO companies through an EquityZen investment vehicle.
About 4D Molecular Therapeutics Stock
4D Molecular Therapeutics, we are unlocking the full potential of the gene therapy field. Our customized AAV vectors can deliver genes to any cell in the body to eradicate disease.
Funding History
| August 2015 | $7.0M |
|---|---|
| September 2017 | $3.0M |
Management
Co-Founder
David Schaffer
COO
Anthony Davies
Co-Founder, President & CEO
David Kirn
Press
Endpoints News - May, 1 2018
Roche boosts its gene therapy game, expanding partnership with 4D Molecular TherapeuticsBusiness Wire (press release) - Apr, 30 2018
4DMT and ROCHE Expand Ophthalmology Partnership to Develop and Commercialize Multiple AAV Gene Therapy ...Business Wire (press release) - Sep, 19 2017
4D Molecular Therapeutics Receives $3 Million Follow-On Funding from Cystic Fibrosis Foundation Therapeutics for ...EquityZen does not have an affiliation with, formal relationship with, or endorsement from any companies featured above. This profile is based on publicly available information and is intended to be informative in nature.
Some data provided by Crunchbase
EquityZen Recognized As:
